Abstract: The present invention provides a chimeric protein that has a modular structure and comprises a receptor binding domain (RBD) from the spike protein (S) of coronaviruses, a segment able to bind the core antigen from the Hepatitis B Virus (HBcAg), a segment including six consecutive histidine residues (HHHHHH), and two spacer segments. In this chimeric protein the aforementioned segments are arranged in a specific order, and the protein is able to form hybrid nanoparticles with HBcAg. The chimeric protein is part of vaccine compositions used for the prevention of coronavirus infections. Therefore, the invention discloses a method for the prevention of coronavirus infections, whereby a vaccine composition comprising said chimeric protein is administered.

Abstract: Catalytic dehydrogenation of a light alkane gas on a metal oxide catalyst is achieved by (a) pretreating the metal oxide catalyst with dimethylether (DME); and (b) reacting the alkane gas catalytically on the catalyst in a dehydrogenation reaction, under conditions wherein the pretreating improves product yield of the reaction.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: Disclosed are catalyst compositions containing cobalt II cations (Co2+) on a support. In embodiments, the catalyst compositions are free of chromium and/or a precious metal. Also disclosed are methods of preparing such catalyst compositions and methods of using such catalyst compositions, for example, to dehydrogenate light alkane and/or light alkene gas.

Abstract: Disclosed are methods of dehydrogenating a light alkane gas (and/or light alkene gas), which include adding hydrogen (H2) to the light alkane gas (and/or light alkene gas) in the presence of a catalyst composition containing zirconium oxide. Also disclosed are catalyst compositions containing zirconium oxide and methods of preparation thereof, where the catalyst compositions are useful in methods of dehydrogenating light alkane gas.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: Zeolites having highly dispersed bimetallic clusters, uniformly distributed in size and composition, encapsulated therein are disclosed. Metal encapsulation and alloying is conferred by introducing ligated metal cation precursors into zeolite synthesis gels, which are subsequently crystallized hydrothermally to form zeolites with metal cations occluded in the pores. The ligated cations are anchored to the zeolite framework via siloxane bridges which enforces their uniform dispersion throughout the zeolite crystals. Treatment of the crystallized zeolites in O2 and then H2 forms bimetallic clusters, which remain narrowly distributed in size and composition.

Abstract: Provided is a method of encapsulating a metal in a zeolite. The method comprises inserting a metal precursor into a parent zeolite, and then converting the parent zeolite to a zeolite having a higher framework density than the parent zeolite. The conversion is achieved without the need of an organic structure directing agent.

Abstract: Zeolites having highly dispersed bimetallic clusters, uniformly distributed in size and composition, encapsulated therein are disclosed. Metal encapsulation and alloying is conferred by introducing ligated metal cation precursors into zeolite synthesis gels, which are subsequently crystallized hydrothermally to form zeolites with metal cations occluded in the pores. The ligated cations are anchored to the zeolite framework via siloxane bridges which enforces their uniform dispersion throughout the zeolite crystals. Treatment of the crystallized zeolites in O2 and then H2 forms bimetallic clusters, which remain narrowly distributed in size and composition.

Abstract: Provided is a method for preparing a zeolite having a Si/Al ratio of at least 10 by interzeolite transformation in the absence of an organic structure directing agent. The method is more cost effective and less equipment intensive as it eliminates the costly organic structure directing agent and the waste treatment at the plant.

Abstract: Provided is a method of encapsulating a metal in a zeolite. The method comprises inserting a metal precursor into a parent zeolite, and then converting the parent zeolite to a zeolite having a higher framework density than the parent zeolite. The conversion is achieved without the need of an organic structure directing agent.

Abstract: Provided is a method for preparing a zeolite having a Si/Al ratio of at least 10 by interzeolite transformation in the absence of an organic structure directing agent. The method is more cost effective and less equipment intensive as it eliminates the costly organic structure directing agent and the waste treatment at the plant.

Abstract: Immobilized nitronyl nitroxide active sites on the surface of a porous inorganic oxide support act as efficient and rapid oxidants for NO, reacting with >99% of the NO under flow conditions through a packed bed; and, in a parallel configuration with nitroxyl radical active sites, act to remove >99% of both NO and NO2 from a gas mixture, with >95% of the active sites participating in NOx trapping.

Abstract: Immobilized nitronyl nitroxide active sites on the surface of a porous inorganic oxide support act as efficient and rapid oxidants for NO, reacting with >99% of the NO under flow conditions through a packed bed; and, in a parallel configuration with nitroxyl radical active sites, act to remove >99 % of both NO and NO2 from a gas mixture, with >95% of the active sites participating in NOx trapping.

Abstract: A process for the oxidation of hydrocarbons comprises contacting the hydrocarbon with an oxygen-containing gas in the presence of a catalyst comprising a microporous solid support, preferably a zeolite, having from 8- to 12-ring open windows and comprising non-framework metal cations selected from manganese, iron, cobalt, vanadium, chromium, copper, nickel, and ruthenium, and mixtures thereof, providing that the oxygen-containing gas does not contain significant amounts of added hydrogen. The catalyst is novel and forms part of the invention. The process may be used for oxidation of alkanes, cycloalkanes, benzene and alkylbenzenes, and is suitable for use in regioselective terminal oxidation of straight chain alkanes and for selective oxidation/separation of p-dialkylbenzenes from an alkylbenzene mixture, for example, p-xylene from an isomeric mixture of xylenes.

Abstract: High octane C7 hydrocarbons, particularly 2,2,3-trimethylbutane (“triptane”) and 2,2,3-trimethyl-but-1-ene (“triptene”) (collectively “triptyls”) are produced by homologation of a feed comprising dimethyl ether and/or methanol and optionally including one or more aliphatic hydrocarbons in the presence of certain acidic zeolite catalysts. The process can be carried out at temperatures lower than those previously used for conversion of dimethyl ether and/or methanol to higher alkanes, including C7 alkanes, and results in selective production of triptane and/or triptene with relatively little isomerization to or production of other C7 alkanes.

Abstract: Immobilized nitronyl nitroxide active sites on the surface of a porous inorganic oxide support act as efficient and rapid oxidants for NO, reacting with >99% of the NO under flow conditions through a packed bed; and, in a parallel configuration with nitroxyl radical active sites, act to remove >99 % of both NO and NO2 from a gas mixture, with >95% of the active sites participating in NOx trapping.

Abstract: High octane C7 hydrocarbons, particularly 2,2,3-trimethylbutane (“triptane”) and 2,2,3-trimethyl-but-1-ene (“triptene”) (collectively “triptyls”) are produced by homologation of a feed comprising dimethyl ether and/or methanol and optionally including one or more aliphatic hydrocarbons in the presence of certain acidic zeolite catalysts. The process can be carried out at temperatures lower than those previously used for conversion of dimethyl ether and/or methanol to higher alkanes, including C7 alkanes, and results in selective production of triptane and/or triptene with relatively little isomerization to or production of other C7 alkanes.